Dapolsertib

Dapolsertib is an investigational new drug that is being evaluated for the treatment of cancer. It is dual inhibitor of PIM family of serine/threonine protein kinases and mutant forms of FMS-related tyrosine kinase 3 (FLT3) that is being developed by Ryvu Therapeutics SA.[1]

## References

1. ↑ "FLT3 inhibitors in acute myeloid leukemia". Journal of Hematology & Oncology 11 (1). December 2018. doi:10.1186/s13045-018-0675-4. PMID 30514344.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Dapolsertib. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Dapolsertib&oldid=4038306"